Monitorización de factores de la coagulación en cirugía

Juan Eduardo Megías-Vericat, Santiago Bonanad-Boix, María Remedios Marqués-Miñana, José Luis Poveda-Andrés

Resumen


Objetivo: El manejo de las cirugías en pacientes hemofílicos es complejo y  requiere de un ajuste adecuado de los factores de coagulación para evitar  complicaciones hemorrágicas y un consumo elevado. El objetivo de esta  revisión sistemática es analizar los estudios farmacocinéticos publicados en  cirugía en pacientes con hemofilia, las metodologías empleadas, las principales  covariables farmacocinéticas y las recomendaciones de las guías  clínicas.

Método: Se ha realizado una búsqueda estructurada sin restricciones de fecha  ni idioma en Pubmed, Cochrane y Database of Abstracts of Reviews of  Effects empleado los mismos términos de búsqueda: (hemophilia or  haemophilia), surgery y (pharmacokinetics or PK). 

Resultados: La búsqueda sistemática obtuvo 186 resultados, de los que seleccionamos 34 artículos. Muchos estudios analizaban el uso de  erfusiones continuas con el objetivo de lograr niveles estables de factor VIII o  IX y reducir el consumo global, aunque su empleo ha caído en desuso. Durante  décadas las guías clínicas recomendaban realizar estudios  farmacocinéticos completos previos a la cirugía (9-11 muestras), según los  cuales se ajusta la dosis prequirúrgica, así como la velocidad de infusión en caso de perfusión continua basándose en el aclaramiento calculado. Otra aproximación es el empleo de modelos poblacionales farmacocinéticos, ajustando con un número más limitado de muestras. Estas  estimaciones farmacocinéticas prequirúrgicas pierden validez tan pronto como  se inicia un procedimiento quirúrgico, y tienen que ajustarse con niveles pico y valle periódicos. Además, las guías clínicas recomiendan, en función del  populationtipo de cirugía, mantener los niveles de factores VIII y IX por  encima de los umbrales específicos durante periodos, por lo que resulta  fundamental emplear la farmacocinética durante el proceso pre y  postquirúrgico. En los últimos años se han desarrollado modelos poblacionales  farmacocinéticos de factores VIII y IX específicos para cirugía. Las principales  covariables de estos modelos son la edad, el grupo sanguíneo y el tipo de  cirugía para el factor VIII, y la edad y el peso corporal para el factor IX.

Conclusiones: La farmacocinética puede permitir ajustar de forma individual y  protocolizada las cirugías en pacientes hemofílicos. El desarrollo de modelos farmacocinéticos poblacionales específicos para cirugía, incluyendo los factores de vida media extendida, permitirá optimizar estos tratamientos, con potencial reducción del consumo y las  estancias hospitalarias.

 


Palabras clave


Cirugía; Farmacocinética; Factor VIII; Factor IX; Estimación bayesiana

Texto completo:

PDF (English) PDF

Referencias


Fischer K, Ljung R. Primary prophylaxis in haemophilia care: Guideline update

Blood Cells Mol Dis. 2017;67:81-5. DOI: 10.1016/j.bcmd.2017.02.004

Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R,

et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with

severe hemophilia. N Engl J Med. 2007;357(6):535-44. DOI: 10.1056/NEJMoa067659

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al.

WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia.

;26 Suppl 6:1-158.

Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, et al. Performing

and interpreting individual pharmacokinetic profiles in patients with Hemophilia

A or B: Rationale and general considerations. Res Pract Thromb Haemost.

;2(3):535-48. DOI: 10.1002/rth2.12106

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies

that evaluate healthcare interventions: explanation and elaboration. BMJ.

;339:b2700. DOI: 10.1136/bmj.b2700

Lee M, Morfini M, Schulman S, Ingerslev J; the Factor VIII/ Factor IX Scientific and

Standardization Committee of the International Society for Thrombosis and Haemostasis.

The design and analysis of pharmacokinetic studies of coagulation factors

[Internet]; 2001 [accessed: 04/13/2021]. Available at: https://www.isth.

org/members/group_content_view.asp?group=100348&id=159244

Kasper CK, Boylen AL, Ewing NP, Luck JV Jr, Dietrich SL. Hematologic management

of hemophilia A for surgery. JAMA. 1985;253(9):1279-83.

Ruffo S, Messori A, Longo G, Matucci M, Morfini M, Rossi-Ferrini P. A microcomputer

program for individualizing factor VIII dosage in hemophilia patients undergoing

major surgery. Comput Methods Programs Biomed. 1986;23(1):37-46. DOI:

1016/0169-2607(86)90078-7

Longo G, Messori A, Morfini M, Baudo F, Ciavarella N, Cinotti S, et al. Evaluation

of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and

description of a nomogram for dosing calculations. Am J Hematol. 1989;30(3):140-

DOI: 10.1002/ajh.2830300305

Ruffo S, Messori A, Grasela TH, Longo G, Donati-Cori G, Matucci M, et al.

A calculator program for clinical application of the Bayesian method of predicting

plasma drug levels. Comput Programs Biomed. 1985;19(2-3):167-77. DOI:

1016/0010-468x(85)90008-x

Durisová M, Dedík L, Bátorová A, Sakalová A, Hedera J. Pharmacokinetics of factor

VIII in hemophilia A patients assessed by frequency response method. Methods

Find Exp Clin Pharmacol. 1998;20(3):217-26.

Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. A limited sampling strategy

for estimating individual pharmacokinetic parameters of coagulation factor VIII in

patients with hemophilia A. Ther Drug Monit. 2007;29(1):20-6. DOI: 10.1097/

FTD.0b013e3180311384

Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted

dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol.

;82(4):729-34. DOI: 10.1111/j.1365-2141.1992.tb06951.x

Hay CR, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and

major bleeding. Blood Coagul Fibrinolysis. 1996;7 Suppl 1:S15-9.

Rochat C, McFadyen ML, Schwyzer R, Gillham A, Cruickshank A. Continuous

infusion of intermediate-purity factor VIII in haemophilia A patients undergoing

elective surgery. Haemophilia. 1999;5(3):181-6. DOI: 10.1046/j.1365-2516.

00309.x

Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, et al. Stability,

efficacy, and safety of continuously infused sucrose-formulated recombinant factor

VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia.

;15(3):676-85. DOI: 10.1111/j.1365-2516.2008.01978.x

Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, et al.

Retrospective analysis of in vivo recovery and clearance during continuous infusion

of recombinant factor VIII products: a single-institution study. Haemophilia.

;23(2):215-21. DOI: 10.1111/hae.13082

Kremer Hovinga ICL, Schutgens REG, van der Valk PR, van Vulpen LFD, Mauser-Bunschoten

EP, Fischer K. Continuous infusion of extended half-life factor VIII (efmoroctocog

alpha) for surgery in severe haemophilia A. Haemophilia. 2018;24(4):e280-3.

DOI: 10.1111/hae.13557

Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically

treated and nanofiltered factor IX concentrate for continuous infusion in

haemophilia patients undergoing surgery. Haemophilia. 1999;5(2):96-100. DOI:

1046/j.1365-2516.1999.00284.x

Hoots WK, Leissinger C, Stabler S, Schwartz BA, White G, Dasani H, et al.

Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine)

in haemophilia B. Haemophilia. 2003;9(2):164-72. DOI: 10.1046/j.1365-

2003.00721.x

Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton

AN, et al. Development of a Web-Accessible Population Pharmacokinetic Service-

Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc. 2016;5(4):e239.

DOI: 10.2196/resprot.6558

Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. The features of clearance

in recombinant factor IX (BeneFIX®). Haemophilia. 2015;21(5):702-7. DOI:

1111/hae.12672

Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, et al.

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic

management in severe haemophilia A. Thromb Haemost. 2016;116(1):1-8.

DOI: 10.1160/TH15-10-0780

Brand B, Gruppo R, Wynn TT, Griskevicius L, López Fernández MF, Chapman M,

et al. Efficacy and safety of pegylated full-length recombinant factor VIII with extended

half-life for perioperative haemostasis in haemophilia A patients. Haemophilia.

;22(4):e251-8. DOI: 10.1111/hae.12963

Gruppo R, López-Fernández MF, Wynn TT, Engl W, Sharkhawy M, Tangada S.

Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with

extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final

results of a multicentre, single-arm phase III trial. Haemophilia. 2019;25(5):773-81.

DOI: 10.1111/hae.13807

Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu

J, et al. Efficacy and safety of long-acting recombinant fusion protein linking factor

IX with albumin in haemophilia B patients undergoing surgery. Haemophilia.

;22(4):e259-66. DOI: 10.1111/hae.12972

Curtin J, Santagostino E, Karim FA, Li Y, Seifert W, Négrier C. Simplifying surgery

in haemophilia B: Low factor IX consumption and infrequent infusions in

surgical procedures with rIX-FP. Thromb Res. 2020;188:85-9. DOI: 10.1016/

j.thromres.2020.02.011

Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, et al. Longacting

recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management

of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol.

;168(1):124-34. DOI: 10.1111/bjh.13112

Diao L, Li S, Ludden T, Gobburu J, Nestorov I, Jiang H. Population pharmacokinetic

modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with

haemophilia B. Clin Pharmacokinet. 2014;53(5):467-77. DOI: 10.1007/s40262-

-0129-7

Hazendonk HC, van Moort I, Fijnvandraat K, Kruip MJ, Laros-van Gorkom BA, van

der Meer FJ, et al. The “OPTI-CLOT” trial. A randomised controlled trial on periOperative

PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia

A. Thromb Haemost. 2015;114(3):639-44. DOI: 10.1160/TH14-11-0925

Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, et

al. A population pharmacokinetic model for perioperative dosing of factor VIII in

hemophilia A patients. Haematologica. 2016;101(10):1159-69. DOI: 10.3324/

haematol.2015.136275

Preijers T, Liesner R, Hazendonk HCAM, Chowdary P, Driessens MHE, Hart DP, et

al. Validation of a perioperative population factor VIII pharmacokinetic model with

a large cohort of pediatric hemophilia a patients. Br J Clin Pharmacol. 2021 Apr

DOI: 10.1111/bcp.14864. Epub ahead of print.

Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, et

al. Population pharmacokinetics of factor IX in hemophilia B patients undergoing

surgery. J Thromb Haemost. 2018;16(11):2196-207. DOI: 10.1111/jth.14292

Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic

modeling for dose setting of nonacog beta pegol (N9-GP), a glyco-

PEGylated recombinant factor IX. J Thromb Haemost. 2012;10(11):2305-12. DOI:

1111/jth.12000

Guidelines for the management of hemophilia (World Federation of Hemophilia).

World Federation of Hemophilia website [Internet]; 2001 [accessed:

/13/2021]. Available at: http://illinoisaap.org/wp-content/uploads/

guidelines-Hemophilia-WHF- 2005.pdf

Simpson ML, Kulkarni R, Escuriola Ettingshausen C, Medom Meldgaard R, Cooper

DL, Klamroth R. Population Pharmacokinetic Modeling Of On-Demand And

Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm

Comparative Pharmacokinetic Study. J Blood Med. 2019;10:391-8. DOI:

2147/JBM.S217539

Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et

al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.

DOI: 10.1111/j.1365-2516.2012.02909.x

Preijers T, Laros-vanGorkom BA, Mathôt RA, Cnossen MH. Pharmacokinetic-guided

dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient

undergoing orthopaedic surgery. BMJ Case Rep. 2019;12(1):bcr-2018-226812.

DOI: 10.1136/bcr-2018-226812

Van Moort I, Bukkems LH, Nieuwenhuizen L, Cnossen MH. Impact of extreme

weight loss on factor VIII concentrate pharmacokinetics in haemophilia. BMJ Case

Rep. 2021;14(4):e238036. DOI: 10.1136/bcr-2020-238036

White GC 2nd, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE. Variability of

in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX

concentrates in patients with hemophilia B. The Mononine Study Group. Thromb

Haemost. 1995;73(5):779-84.

Hazendonk HC, Lock J, Mathôt RA, Meijer K, Peters M, Laros-van Gorkom BA, et

al. Perioperative treatment of hemophilia A patients: blood group O patients are

at risk of bleeding complications. J Thromb Haemost. 2016;14(3):468-78. DOI:

1111/jth.13242

Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans

C, et al. Target plasma factor levels for personalized treatment in haemophilia:

a Delphi consensus statement. Haemophilia. 2017;23:e170-9. DOI: 10.1111/

hae.13215

Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, et al.

Perioperative replacement therapy in haemophilia B: An appeal to “B” more precise.

Haemophilia. 2018;24(4):611-8. DOI: 10.1111/hae.13469

Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Monte-Boquet E, et

al. Cross-sectional comparative study of pharmacokinetics and efficacy between

sucrose-formulated recombinant factor VIII (Kogenate®) and BAY 81-8973 (Kovaltry

®) in patients with severe or moderate haemophilia A in prophylaxis. Haemophilia.

;25(3):e215-8. DOI: 10.1111/hae.13733

Pouplard C, Sattler L, Ryman A, Eschwege V, De Maistre E, Flaujac C, et al.

Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real

life and comparison with non-extended half-life FVIII concentrates. Haemophilia.

;26(2):282-9. DOI: 10.1111/hae.13946

Rodríguez López M, Megías Vericat JE, Albo López C, Bonanad S. Clinical, pharmacokinetic

and economic analysis of the first switch to an extended half-life factor

IX (albutrepenonacog alfa, rFIX-FP) in Spain. BMJ Case Rep. 2020;13(10):e234142.

DOI: 10.1136/bcr-2019-234142

Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting

the pharmacokinetic profiles of individual patients with hemophilia A or B

using a population pharmacokinetic approach: communication from the SSC of the

ISTH. J Thromb Haemost. 2017;15(12):2461-5. DOI: 10.1111/jth.13867

Von Auer CH, Oldenburg J, von Depka M, Escuriola-Ettinghausen C, Kurnik K,

Lenk H, et al. Inhibitor development in patients with hemophilia A after continuous

infusion of FVIII concentrates. Ann N Y Acad Sci. 2005;1051:498-505. DOI:

1196/annals.1361.094

Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, et al.

Continuous infusion in haemophilia: current practice in Europe. Haemophilia.

;18(5):753-9. DOI: 10.1111/j.1365-2516.2012.02810.x

Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic

(PK) Expert Working Group of the International Prophylaxis Study Group (the

IPSG). Tailoring treatment of haemophilia B: accounting for the distribution and

clearance of standard and extended half-life FIX concentrates. Thromb Haemost.

;117(6):1023-30. DOI: 10.1160/TH16-12-0942

Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, et al.

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog

beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two

phase 3 clinical trials. Haemophilia. 2017;23(4):547-55. DOI: 10.1111/hae.13191


Enlaces refback

  • No hay ningún enlace refback.


Incluida en:

Bibliovigilance Dialnet DOAJ Dulcinea EBSCO Embase ESCI Ibecs Latindex MEDES mEDRA MIAR PUBMED REDALYC Redib SciELO SCOPUS Sherpa/Romero

Farmacia Hospitalaria

Sociedad Española de Farmacia Hospitalaria. C/ Serrano n. 40 2º Dcha. - 28001 Madrid

eISSN: 2171-8695 

ISSN-L: 1130-6343

Dep. Legal: M-39835-2012

Correo electrónico de contacto: [email protected]

Los artículos publicados en esta revista se distribuyen con la licencia: Creative Commons Attribution 4.0.

La revista Farmacia Hospitalaria no cobra tasas por el envío de trabajos, ni tampoco cuotas por la publicación de sus artículos.